Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy

COMBINATION_PRODUCT2 trials

Sponsors

Changzhou No.2 People's Hospital

Conditions

Gastric CancerNon-small Cell Lung Cancer

Phase 2

FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC

RecruitingNCT06403111

Changzhou No.2 People's HospitalNon-small Cell Lung Cancer

Start: 2024-06-01End: 2026-06-01Target: 62Updated: 2024-12-20

FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer

RecruitingNCT06405113

Changzhou No.2 People's HospitalGastric Cancer

Start: 2024-06-01End: 2027-06-01Target: 198Updated: 2025-02-20

Related Papers

Fecal microbiota transplantation combined with sintilimab and SOX as first-line treatment for advanced gastric cancer (FMT-JSNO-01): A prospective, multicenter, double-blind, randomized placebo-controlled phase II trial.

Journal of Clinical Oncology2025-05-28

Faecal microbiota transplantation combined with platinum-based doublet chemotherapy and tislelizumab as first-line treatment for driver-gene negative advanced non-small cell lung cancer (NSCLC): study protocol for a prospective, multicentre, single-arm exploratory trial

BMJ Open2025-03-011 citations